Pharma Pulse 2/27/25: The Threat of Misinformation on Public Health, Congress Turns Attention to PBM Reform, Sort of & more
The Threat of Misinformation on Public Health
In this Pharmaceutical Executive video interview, Jen Butler, Chief Commercial Officer of Pleio, discusses the significant threat of misinformation to public health and how emotional appeal plays a part.
Congress Turns Attention to PBM Reform, Sort of
At what was supposed to be a hearing to discuss PBM reform, some in Congress veered off into discussions about Medicaid and maternal health, and even Elon Musk.
Lilly to Spend $27 Billion to Bolster US Drug Manufacturing
Eli Lilly & Co. will spend at least $27 billion to build four US manufacturing plants, the latest company to brace for the potential impact of President Donald Trump’s tariffs.
The Estée Lauder Companies Inc. announced a collaboration with biotechnology company, Serpin Pharma, that aims to explore how their anti-inflammatory research can be applied in cosmetics to deliver significant skin care longevity benefits to consumers around the world.
🚨 BREAKING: President Trump signs an executive order that’s expected to provide greater healthcare price transparency for patients.🚨 The latest in Pharmaceutical Commerce Magazine.
Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs
